12:00 AM
 | 
Jul 03, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/30 cls
Anadys (ANDS) JMP Securities Adam Cutler Downgrade Market perform (from strong buy) -56% $2.92
Piper Jaffray Edward Tenthoff Downgrade Underperform (from market outperform)
ThinkEquity Andrew McDonald Price target Sell
Cutler downgraded the stock after ANDS suspended dosing in a Phase Ib trial of ANA975 to treat HCV because toxicology studies showed "intense" immune stimulation in animals (see B18).
Tenthoff lowered his target to $6 from $18 on the ANA975 news.
McDonald lowered his target to $3.50 from $7. He said his target values...

Read the full 691 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >